Solid Margins, Financial Strategies, and Earnings Reports Support Long-Term Growth in Biotech - Research Report on Gilead Sciences, Celgene, Onyx Pharmaceuticals, Questcor, and Amgen

NEW YORK, August 6, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Gilead Sciences Inc. (NYSE: GILD), Celgene Corporation (NASDAQ: CELG), Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), and Amgen Inc. (NASDAQ: AMGN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Gilead Sciences Inc. Research Report

On July 25, 2013, Gilead Sciences Inc. (Gilead) released its Q2 2013 financial results. The Company reported total revenues of $2.8 billion, up 15.1% YoY, as product sales increased 14.7% YoY to $2.7 billion, driven primarily by growth in Gilead's antiviral franchise, in Q2 2013. On the other hand, royalty, contract, and other revenues were up31.2% YoY to $110.1 million. Net income attributable to the Company was up 8.6% YoY to $772.6 million, while diluted EPS in Q2 2013 remained unchanged at $0.46 from Q2 2012. The Full Research Report on Gilead Sciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-02/GILD]

--

Celgene Corporation Research Report

On August 1, 2013, Celgene Corporation (Celgene) announced its intention to offer senior unsecured notes under a shelf registration statement on Form S-3 on file with the Securities and Exchange Commission, subject to market and other conditions. Celgene reported that the interest rate, the maturity dates, and other key terms of the offering will be determined at the time of pricing. The Company stated that it intends to use the net proceeds from the offering for general corporate purposes, which may include, without limitation, further development of Celgene's clinical and pre-clinical programs, capital expenditures, general corporate development activities, meeting working capital needs, share repurchases of common stock, and repayment of some or all of its outstanding commercial papers. The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-02/CELG]

--

Onyx Pharmaceuticals, Inc. Research Report

On July 31, 2013, Onyx Pharmaceuticals, Inc. (Onyx Pharmaceuticals) announced that it will release its Q2 2013 financial results after the market closes on Thursday, August 8, 2013. Onyx Pharmaceuticals reported that it will hold a webcast and conference call with the financial community for the discussion of its Q2 2013 financial results and general business overview on the same day at 5:00 p.m. ET (2:00 p.m. PT). The Full Research Report on Onyx Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-02/ONXX]

--

Questcor Pharmaceuticals, Inc. Research Report

On July 30, 2013, Questcor Pharmaceuticals, Inc. (Questcor) released its Q2 2013 financial results. The Company reported that its net income was up 66.5% YoY to $69.1 million, and diluted EPS was up 72.3% YoY to $1.12, during the quarter. Net sales were up 64.1% YoY to $184.6 million, primarily attributable to the expanded usage of H.P. Acthar Gel (repository corticotropin injection) by rheumatologists in the treatment of patients suffering from dermatomyositis; polymyositis; systemic lupus erythematosus; and rheumatoid arthritis, besides the growth of nephrological and neurological prescriptions for the treatment of nephrotic syndrome (NS) and multiple sclerosis (MS) relapses and infantile spasms (IS), respectively. Steve Cartt, Chief Operating Officer of Questcor, stated, "Total new paid prescriptions for Acthar were approximately 2,250 to 2,275 in the second quarter, an increase of about 35% year-over-year." The Full Research Report on Questcor Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-02/QCOR]

--

Amgen Inc. Research Report

On July 30, 2013, Amgen Inc. (Amgen) released its Q2 2013 financial results. The Company's revenues were up 4.5% YoY to $4.7 billion, as total product sales increased 9.4% YoY to $4.6 billion, driven by Enbrel (etanercept), Neulasta (pegfilgrastim), XGEVA (denosumab), and Prolia (denosumab), during the quarter. Net income was down 0.6% YoY to $1.3 million, and diluted EPS was up 2.5% YoY to $1.65. Robert A. Bradway, Chairman and CEO of Amgen, said, "We saw solid product trends during the second quarter and are carrying good momentum into the second half." Bradway added, "We continue to make excellent progress with our pipeline of innovative molecules and look forward to multiple data readouts in 2014, including pivotal Phase 3 data for our cholesterol-lowering agent, AMG 145, in the first quarter." For full-year 2013, Amgen expects revenues to be at the upper end of $17.8 billion to $18.2 billion; adjusted EPS to be in the range of $7.30 to $7.45; adjusted tax rate to be in the range of 9% to 10%; and capital expenditures to be approximately $700 million. The Full Research Report on Amgen Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-02/AMGN]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Investors' Reports